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The crystal structure of the extracellular domain of growth hormone
receptor complexed to its ligand, growth hormone, has been known
since 1992. However, no information exists for the unliganded form
of the receptor. The human growth hormone receptor's extracellular
ligand-binding domain, encompassing amino-acid residues 1±238, has
been expressed in Escherichia coli, puri®ed by anion ion-exchange
chromatography and crystallized in its unliganded state by the
hanging-drop vapour-diffusion method in 100 mM HEPES pH 7.0
containing 27.5%(w/v) PEG 5000 monomethyl ether and 200 mM
ammonium sulfate as the co-precipitants. The crystals belong to the
othorhombic space group C2221, have unit-cell parameters a = 99.7,
b = 112.2, c = 93.2 AÊ and diffract to 2.5 AÊ resolution using
synchrotron radiation. The crystal structure will shed light on the
nature of any conformation changes that occur upon ligand binding
and will provide information to develop potential low-molecular-
weight agonists/antagonists to treat clinical diseases in which the
growth hormone receptor is implicated.
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1. Introduction
Growth hormone causes a diverse range of
biological activities including bone growth,
lactation, regulation of lipid and carbohydrate
metabolism and actions on the reproductive
and immune systems (Silva et al., 1998). In
order to accomplish these actions, growth
hormone must bind to its speci®c cell-surface
receptor to activate the requisite intracellular
signal transduction pathways. The growth
hormone receptor is a type I transmembrane
receptor that belongs to the cytokine/haemo-
poietin receptor superfamily (Bazan, 1990).
This family of receptors is characterized by the
presence of ®bronectin type III modules,
conserved cysteine residues, a cytokine-
receptor homology region and the WSXWS
motif within the extracellular ligand-binding
domain (Wells & de Vos, 1996). The intra-
cellular domains of these receptors lack
intrinsic kinase activity; instead, they contain a
proline-rich region that serves as a binding site
for a family of cytoplasmic tyrosine kinases
called Janus kinases (JAKs). Human growth
hormone exists as a monomer and has two
binding sites for the extracellular domain of
the growth hormone receptor. It is believed
that ligand binding induces receptor dimer-
ization and activation of JAKs by transphos-
phorylation. (Fuh et al., 1992). Activated JAKs
in turn phosphorylate tyrosine residues on the
receptor's cytoplasmic domain and on down-
stream signalling molecules, resulting in
altered cellular proliferation, differentiation,
survival and metabolism depending on the cell
type involved.
Recent evidence suggests that preformed
dimers of the growth hormone receptor exist
prior to ligand binding (Ross et al., 2001; Gent
et al., 2002). We have expressed, puri®ed and
obtained crystals of the extracellular ligand-
binding domain of the growth hormone
receptor in the absence of growth hormone.
This domain encompasses amino-acid residues
1ÿ238 and the expressed protein has an
apparent molecular weight of 30 kDa when
analysed by SDS±PAGE. We anticipate that
the crystal structure will shed light on how
hormone binding to its receptor might lead to
conformational change and receptor activa-
tion.
2. Experimental procedures and results
2.1. Cloning, expression and purification
The recombinant human growth hormone
receptor extracellular ligand-binding domain
(hGHBP) was expressed in Escherichia coli
strain BL21-Codon Plus (DE3)-RIL after the
hGHBP cDNA coding sequence for residues
1±238 was ligated into the pET20b(+) vector.
Codon Plus cells were grown in 500 ml 2YT
medium by shaking at 200 rev minÿ1 at 310 K
in 2 l ¯asks to an A600 of 0.8, after which IPTG
(1.0 mM) was added. The cells were incubated
for an additional 3 h at 293 K, harvested,
PMSF was added to a ®nal concentration of
0.2 mM and the paste was stored frozen at
crystallization papers
203 K overnight. In a modi®cation of the
method of Sakal et al. (2000), the inclusion-
body pellet obtained from 2 l bacterial
culture by French Press lysis and washing
was solubilized in 400 ml 4.5 M urea
buffered with 40 mM Tris base pH 10.4.
l-Cysteine was added to 0.1 mM and the
clear solution was stirred at 277 K for 48 h.
This solution was then dialyzed for 48 h
against six changes of 10 mM Tris±HCl pH
8.1 at 277 K. The solution was subsequently
loaded at 120 ml hÿ1 onto a Q-Sepharose
column (1.6  20 cm) pre-equilibrated with
10 mM Tris±HCl pH 8.1 at 277 K. Elution
was carried out with a continuous NaCl
gradient (0±0.4 M) in the same buffer.
Fractions eluting between 0.05 and 0.25 M
NaCl were analyzed by 12.5% SDS±PAGE
in the presence or absence of reducing
agents and fractions judged to be greater
than 95% purity were pooled.
2.2. Crystallization
Crystallization trials were carried out by
the hanging-drop vapour diffusion method
at 295 K using crystallization screens
described by Jancarik & Kim (1991) and
Cudney et al. (1994). A 2 ml droplet of
concentrated growth hormone receptor
extracellular ligand-binding domain
(4 mg mlÿ1) was mixed in a 1:1 ratio with the
reservoir solution and equilibrated against
1 ml reservoir solution. Crystals initially
took ®ve months to appear in condition
No. 26 of Hampton Screen 2 [Hampton
Research, California, USA; 100 mM MES
pH 6.5 containing 30%(w/v) PEG 5000
monomethyl ether and 200 mM ammonium
sulfate], growing as small rods. Streak-
seeding from these crystals into fresh drops
resulted in signi®cantly larger crystals that
grew within two weeks. A combination of
streak-seeding and optimization of pH and
precipitant concentration resulted in crystals
that were deemed to be suitable for
diffraction studies. The largest crystals were
obtained using a reservoir solution
consisting of 100 mM HEPES pH 7.0
containing 27.5%(w/v) PEG 5000 mono-
methyl ether and 200 mM ammonium
sulfate (Fig. 1).
2.3. Data collection
Prior to data collection, a single crystal
was transferred into a stabilizing solution of
100 mM HEPES pH 7.0 containing
30%(w/v) PEG 5000 monomethyl ether and
200 mM ammonium sulfate and sealed
within a glass capillary for transport at room
temperature to the Advanced Photon
Source, Chicago, USA. The crystal was
soaked in a stabilizing solution containing
5%(v/v) glycerol for 5 min, ¯ash-cooled to
100 K and exposed to X-rays. An X-ray data
set was measured on a MAR Research
CCD.165 detector on BioCARS beamline
14-ID-B. The data set extended to 2.5 AÊ
resolution (Fig. 2). The crystals were found
to belong to space group C2221, with unit-
cell parameters a = 99.7, b = 112.2, c = 93.2 AÊ .
The images were processed and scaled using
the HKL program package (Otwinowski &
Minor, 1997) and the statistics are shown in
Table 1. A total of 17 070 unique re¯ections
were measured with an overall redundancy
of 35.7. The merged data set is 92.8%
complete to 2.5 AÊ resolution, with an Rsym of
8.3% and an I/(I) of 20.2. The calculated
Matthews coef®cient (VM) of 2.41 AÊ
3 Daÿ1
suggested the presence of two molecules in
the asymmetric unit and a solvent content of
about 45% (Matthews, 1968). There was no
peak observed in the self-rotation function
that would con®rm the presence of twofold
non-crystallographic symmetry, although we
could not exclude the likelihood that dimers
of the extracellular ligand-binding domain
exist in the crystal. However, biochemical
evidence using size-exclusion chromato-
graphy suggests that the expressed domain
exists as a monomer. Currently, there is
debate within the literature as to whether
the growth hormone receptor exists as a
preformed dimer or undergoes a conforma-
tional change in response to growth-
hormone binding (Frank, 2002). We plan to
solve the crystal structure using the method
of molecular replacement based on the
published model for the holo-receptor
complex (de Vos et al., 1992). The avail-
ability of the crystal structure for the un-
liganded growth hormone receptor's
extracellular domain will thus provide some
insights into its mode of action..
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Figure 1
Growth hormone receptor extracellular ligand-
binding domain crystals. Dimensions are 0.20 
0.05  0.05 mm.
Figure 2
A representative 1 oscillation image of data
collected from a crystal of the unliganded human
growth hormone receptor extracellular ligand-
binding domain, showing Bragg re¯ections extending
beyond 2.5 AÊ .
Table 1
Crystal data and X-ray diffraction data-collection
statistics.
Values in parentheses are for the highest resolution bin
(approximate 0.1 AÊ interval).
X-ray source Beamline 14-ID-B,
APS (Chicago, USA)
X-ray wavelength (AÊ ) 0.99988
Temperature (K) 100
Space group C2221
Unit-cell parameters (AÊ ) a = 99.7, b = 112.2,
c = 93.2
Resolution (AÊ ) 2.5
Total observations 609914
Total No. unique re¯ections 17070
Data completeness (%) 92.8 (52.5)
Rsym² (%) 8.3 (33.1)
I/(I) 20.2 (3.2)
² Rsym =
PI ÿ hIi=PI, where I is the intensity measure-
ment for a given re¯ection and hIi is the average intensity for
multiple measurements of this re¯ection.
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